HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Nifedipine (Adalat)

A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.

Also Known As:

Adalat; AWD Pharma Brand of Nifedipine; Adcock Ingram Brand of Nifedipine; BAY-a-1040; Bay-1040; Bayer Brand of Nifedipine; Cordipin; Cordipine; Corinfar; Fenigidin; KRKA Brand of Nifedipine; Korinfar; Nifangin; Nifedipine Monohydrochloride; Nifedipine-GTIS; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia; Procardia XL; Vascard; BAY a 1040; BAYa1040; Bay 1040; Bay1040; Monohydrochloride, Nifedipine; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Orion Brand; Nifedipine Pfizer Brand; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester

Networked: 4890 relevant articles (581 outcomes, 895 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyridines: 41
    - Dihydropyridines: 177
      - Nifedipine: 4890
        nilvadipine: 111
        mepirodipine: 38
        darodipine: 18
        ryodipine: 18
        niludipin: 16
        1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester: 12
        CD 832: 7
        KW 3049: 6
        mebudipine: 6
        FR 7534: 4
        dehydronifedipine: 3
        YM 430: 3
        Depin-E: 2
        1,4-dihydro-2,6-dimethyl--4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl-1-methylethyl ester: 1
        Antrolin: 1
        dibudipine: 1
        nifedipine drug combination acebutolol: 1
        nifedipine-co-dergocrine combination: 1
        nitrosonifedipine: 1
        YC 170: 1
        1,4-dihydro-2,6--dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid bis(2-cyanoethyl) ester
        1,4-dihydro-2,6-dimethyl-4-(2,4-dinitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
        1,4-dihydro-2,6-dimethyl-4-(3-methylphenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
        1,4-dihydro-2,6-dimethyl-4-(4-methylphenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
        1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester
        1,4-dihydro-2,6-dimethyl-4--(3-nitrophenyl)pyridine-3-carboxylic acid-5-carboxylic methyl ester
        2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid
        2-(2-(2-(2-chloro-4-(6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy)acetylamino)ethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester
        BAY-k 9320
        BAY-P 8857
        DHM 9
        dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate
        menidipine
        mesudipine
        MPC 2101
        OPC 13463
        PPK-12
        PPK-5

Experts

1.	Kirwan, Bridget-Anne: 13 articles (04/2010 - 09/2004)
2.	Lubsen, Jacobus: 12 articles (04/2010 - 09/2004)
3.	Poole-Wilson, Philip A: 12 articles (03/2008 - 09/2004)
4.	de Brouwer, Sophie: 11 articles (04/2010 - 03/2005)
5.	Yamagishi, S: 10 articles (11/2007 - 01/2003)
6.	Mancia, Giuseppe: 8 articles (06/2015 - 03/2002)
7.	Motro, Michael: 8 articles (09/2013 - 06/2002)
8.	Shemesh, Joseph: 7 articles (09/2013 - 06/2002)
9.	Hosoda, Saichi: 7 articles (01/2010 - 01/2002)
10.	Wagener, Gilbert: 7 articles (08/2007 - 03/2003)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1998 - "The results obtained show that Adalat in dosage 60 mg daily during 7 days is most effective in cases with concomitant border-line hypertension. " 01/01/1991 - "Nifedipine turned out most effective in patients of functional class II with arterial hypertension." 01/01/2007 - "The dose-dependent increased efficacy and the markedly improved safety profile of bedtime as compared to morning administration of nifedipine GITS should be taken into account when prescribing this CCB in the treatment of essential hypertension." 10/01/2015 - "Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension." 12/01/1987 - "In hypertension a similar antihypertensive effect to nifedipine has been found, while a significantly greater lowering of blood pressure was seen than that obtained with a diuretic. "
2.	Angina Pectoris 01/01/2006 - "Professor Hashimoto demonstrated that nifedipine could increase coronary blood flow even in extremely low dosages, and Professor Kimura found that nifedipine is highly efficacious in preventing anginal attacks in patients with angina pectoris, particularly those with variant form of angina. " 01/01/1987 - "For patients with angina pectoris, a plasma concentration range that is associated with optimal treatment has not been defined, since large inter-individual variations in the nifedipine plasma concentration were observed in effectively treated patients. " 08/01/1990 - "These salutary hemodynamic responses of nifedipine appear to be beneficial for patients with effort angina pectoris." 01/16/1989 - "Results from a 14-week, open-label, crossover multicenter trial completed by 91 patients with chronic stable angina pectoris demonstrate that patients treated with standard nifedipine capsules may be switched to equivalent total 24-hour doses of nifedipine GITS and achieve comparable or improved efficacy (due to improved compliance) with a more favorable side-effects profile. " 04/01/1988 - "To assess the dosing equivalency and the early and late antianginal efficacy of a gastrointestinal therapeutic system for once-daily, continuous-release nifedipine (N-GITS), 10 patients with stable angina pectoris, who were previously receiving chronic treatment with nifedipine, completed a 12-week trial comparing N-GITS with standard nifedipine. "
3.	Ischemia 04/01/1997 - "Endothelium-dependent relaxation after ischemia was significantly improved with all three drugs in a dose-dependent fashion; nifedipine was found to be the more potent. " 11/01/1993 - "Nifedipine therapy (immediate release) was effective in control of ischemia only when both ambulatory and office-measured blood pressure were controlled." 11/01/1993 - "The aims of this study were 1) to evaluate the role of blood pressure and associated neural tonicity in ambient ischemia of a group of hypertensive patients with stable angina, and 2) to determine the efficacy of immediate release nifedipine therapy in controlling the total ischemic burden in both office-measured and ambulatory blood pressure. " 04/01/2012 - "Nifedipine ameliorates ischemia-induced revascularization in diet-induced obese mice." 12/01/1995 - "3. A 6-wk nifedipine treatment improved post-ischemic recovery of cardiac parameters and prevented myocardial Na+ accumulation after ischemia and myocardial Ca2+ level and water content elevation after reperfusion of diabetic rats. "
4.	Premature Obstetric Labor (Premature Labor) 01/01/2013 - "The use of Nifedipine therapy in patients with preterm labor between 24-34 weeks of gestational age can be effective in the postponement of labor for 48 hours so that the patient can receive corticosteroid fetal lung maturation therapy. " 08/01/2000 - "Nifedipine as a safe and effective tocolytic agent in the treatment of preterm labor." 01/01/2005 - "A large randomized trial fulfilling the quality items is necessary to assess the real efficacy of nifedipine in preterm labor." 10/01/2015 - "Study Design A secondary analysis of a randomized controlled trial on maintenance nifedipine includes women who remained undelivered after threatened preterm labor for 48 hours. " 10/01/2011 - "This study was done to compare isoxpurine hydrochloride and nifedipine as tocolytic drugs for preterm labor. "
5.	Myocardial Ischemia (Ischemic Heart Diseases) 09/01/1991 - "Thus, asymptomatic ischemic episodes more frequently occur than symptomatic episodes and the administration of slow-release nifedipine is highly effective in suppressing not only symptomatic but also asymptomatic myocardial ischemia in patients with variant angina. " 03/25/1988 - "Group II had improvement in 40% of areas, of significantly worsened areas in 6%, and unchanged areas in 54%, in both groups myocardial ischemia was reduced by therapy, but ISDN improved myocardial perfusion to a considerably greater extent than did nifedipine." 01/01/1982 - "In our patients with CAD, improved RMBF appears to be related to a decrease in coronary vascular tone and suggests a physiologic basis for the beneficial effect of nifedipine in ischemic heart disease." 01/01/1988 - "We conclude that both nifedipine and ISMN in slow-release formulations are equally effective in the treatment of myocardial ischemia. " 08/01/1990 - "Protective effects of pretreatment with intracoronary nifedipine on myocardial ischemia and dysfunction."

Related Drugs and Biologics

1.	Verapamil (Calan)
2.	Calcium
3.	Propranolol (Inderal)
4.	Diltiazem (Cardizem)
5.	Calcium Channels (Calcium Channel)
6.	Atenolol (Tenormin)
7.	Amlodipine (Norvasc)
8.	Isosorbide Dinitrate (Isordil)
9.	Nitroglycerin (Dynamite)
10.	Captopril (Capoten)

Related Therapies and Procedures

1.	Tocolysis
2.	Aftercare (After-Treatment)
3.	Transplants (Transplant)
4.	Drug Therapy (Chemotherapy)
5.	Lithotripsy (Extracorporeal Shockwave Lithotripsy)